European Biotech Acquisition Corp. financial data

Industry
Blank Checks
Location
Epfl Innovation Park Building, Lausanne, Switzerland
State of incorporation
Cayman Islands
Fiscal year end
December 31
Latest financial report
10-K - Q4 2022 - Feb 28, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 69.8 % -76.9%
Debt-to-equity -110 % +8.65%
Return On Equity -5.63 % +73.6%
Return On Assets 0.27 % -77.4%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 129M USD +0.41%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 2.59M USD +184%
Operating Income (Loss) -2.82M USD -156%
Net Income (Loss) Attributable to Parent 343K USD -76.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 308K USD -64.5%
Assets, Current 357K USD -61.1%
Assets 130M USD +1%
Accounts Payable, Current 360K USD +521%
Accrued Liabilities, Current 403K USD -9.88%
Liabilities, Current 796K USD +57.5%
Liabilities 8.55M USD +12.3%
Retained Earnings (Accumulated Deficit) -8.06M USD -20.5%
Stockholders' Equity Attributable to Parent -8.06M USD -20.5%
Liabilities and Equity 130M USD +1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -150K USD -896%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 308K USD -64.5%
Cash and Cash Equivalents, Period Increase (Decrease) -150K USD -109%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 0 USD
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%